| Over a quarter ago |
|
Earnings
|
As of March 31, Milestone… As of March 31, Milestone had cash, cash equivalents, and short-term investments of $100.2M and 29.9 million common shares and 12.3 million common shares issuable upon exercise of pre-funded warrants outstanding. "The beginning of 2022 has been a productive time for Milestone, marked by continued progress advancing our lead Phase 3 program, etripamil, for patients with PSVT," said CEO Joseph Oliveto. "Of note, we were particularly excited by the recent presentation of NODE-302 at the Heart Rhythm Society's Heart Rhythm 2022 conference which highlighted data that continued to support the potential of etripamil as a self-treatment option for patients with PSVT, including those patients experiencing multiple episodes. We remain optimistic for the eventual safety profile of etripamil as clinical trial experience with the repeat dose regimen grows, and we look forward to reporting topline results from our Phase 3 RAPID trial in the middle of the second half of 2022." ShowHide Related Items >><< MIST Milestone Pharmaceuticals - 05/01/22
- Milestone Pharmaceuticals announces data from Phase 3 NODE-302 study
- 02/16/22
- Milestone Pharmaceuticals names David Bharucha as Chief Medical Officer
- 11/15/21
- Milestone Pharmaceuticals announces presentation of NODE-301 trial of etripamil
MIST Milestone Pharmaceuticals - 05/02/22 Piper Sandler
- Milestone data support confidence in Phase III study, says Piper Sandler
- 04/21/22 Piper Sandler
- Piper upgrades Milestone Pharmaceuticals on etripamil confidence
- 04/21/22 Piper Sandler
- Milestone Pharmaceuticals upgraded to Overweight from Neutral at Piper Sandler
MIST Milestone Pharmaceuticals - 03/24/22
- Milestone Pharmaceuticals reports Q4 EPS (40c), consensus (36c)
- 11/12/21
- Milestone Pharmaceuticals reports Q3 EPS (34c), consensus (38c)
MIST Milestone Pharmaceuticals - 04/22/22
- What You Missed On Wall Street On Friday
- 04/22/22
- What You Missed On Wall Street This Morning
- 04/22/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
|
Recommendations
|
Piper Sandler analyst… Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Milestone Pharmaceuticals with a $10 price target after the company over the weekend presented Phase III NODE-302 open label extension data on etripamil. In NODE-302, 60.2% of 188 adjudicated paroxysmal supraventricular tachycardia events treated with etripamil resolved within a median of 15.5 minutes, Tenthoff tells investors in a research note. The analyst says these data support his confidence that etripamil can meet the primary endpoint in the ongoing Phase III RAPID trial of time to conversion to normal sinus rhythm within 30 minutes when reported in September or October. ShowHide Related Items >><< MIST Milestone Pharmaceuticals - 05/01/22
- Milestone Pharmaceuticals announces data from Phase 3 NODE-302 study
- 02/16/22
- Milestone Pharmaceuticals names David Bharucha as Chief Medical Officer
- 11/15/21
- Milestone Pharmaceuticals announces presentation of NODE-301 trial of etripamil
MIST Milestone Pharmaceuticals - 04/21/22 Piper Sandler
- Piper upgrades Milestone Pharmaceuticals on etripamil confidence
- 04/21/22 Piper Sandler
- Milestone Pharmaceuticals upgraded to Overweight from Neutral at Piper Sandler
MIST Milestone Pharmaceuticals - 03/24/22
- Milestone Pharmaceuticals reports Q4 EPS (40c), consensus (36c)
- 11/12/21
- Milestone Pharmaceuticals reports Q3 EPS (34c), consensus (38c)
MIST Milestone Pharmaceuticals - 04/22/22
- What You Missed On Wall Street On Friday
- 04/22/22
- What You Missed On Wall Street This Morning
- 04/22/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
|
Hot Stocks
|
Milestone Pharmaceuticals… Milestone Pharmaceuticals announced data from NODE-302, its Phase 3 open-label extension study of etripamil nasal spray, the company's novel, investigational, calcium channel blocker in patients with paroxysmal supraventricular tachycardia. NODE-302 was a single-arm, open-label extension study of the Phase 3, randomized, double-blind, placebo-controlled NODE-301 study. The primary objective of the NODE-302 study was to assess the safety of patients dosing 70 mg of etripamil over multiple episodes. Patients were eligible to participate in NODE-302 if they dosed themselves for a perceived episode of PSVT in NODE-301. In NODE-302, patients self-administered 70 mg of etripamil nasal spray in response to a perceived PSVT episode after a failed attempt at a vagal maneuver and were monitored for five hours using an ambulatory cardiac monitoring system. The study allowed patients to treat up to 11 unique episodes. Of 198 eligible NODE-301 patients, 169 enrolled in NODE-302 and 105 experienced a perceived episode of PSVT, self-administered etripamil, and were included in the safety population. The calculated median number of treated episodes extrapolated over the course of one year was 3.7. Of the 105 patients who treated themselves for a perceived episode, 92 (88%) had a positively adjudicated PSVT episode. There was a total of 188 positively adjudicated PSVT episodes over a median of 7.4 months follow-up. Overall, the PSVT conversion rate at 30 minutes following etripamil administration was 60.2%, with a median time to conversion of 15.5 minutes. Among 40 patients who self-treated two consecutive episodes, 21 of 26 who converted on their first episode were also successfully converted on their second. Moreover, the need for ED intervention to terminate a PSVT episode was low. Etripamil was generally well-tolerated, with adverse events consistent with those observed in previous trials; the majority of adverse events related to treatment were localized to the nasopharynx administration site, and were mild and brief. ShowHide Related Items >><< MIST Milestone Pharmaceuticals - 02/16/22
- Milestone Pharmaceuticals names David Bharucha as Chief Medical Officer
- 11/15/21
- Milestone Pharmaceuticals announces presentation of NODE-301 trial of etripamil
MIST Milestone Pharmaceuticals - 04/21/22 Piper Sandler
- Piper upgrades Milestone Pharmaceuticals on etripamil confidence
- 04/21/22 Piper Sandler
- Milestone Pharmaceuticals upgraded to Overweight from Neutral at Piper Sandler
MIST Milestone Pharmaceuticals - 03/24/22
- Milestone Pharmaceuticals reports Q4 EPS (40c), consensus (36c)
- 11/12/21
- Milestone Pharmaceuticals reports Q3 EPS (34c), consensus (38c)
MIST Milestone Pharmaceuticals - 04/22/22
- What You Missed On Wall Street On Friday
- 04/22/22
- What You Missed On Wall Street This Morning
- 04/22/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 04/22/22
- Verizon reports Q1 Consumer wireless retail postpaid net losses of 292K
- 04/22/22
- Verizon reports Q1 Business retail postpaid net additions 395K
- 04/22/22
- Verizon reports Q1 Broadband net additions 229,000
- 04/22/22
- Verizon CFO says results show 'strength of core business'
- 04/05/22
- Ubisoft to end ongoing development of 'Ghost Recon Breakpoint'
- 04/05/22
- Ubisoft says 'Rainbow Six Mobile' coming to iOS, Android devices
- 03/22/22
- Microsoft says Lapsus$ stole source code through 'limited' access
- 03/11/22
- Ubisoft experienced cyber security incident last week
- 04/20/22
- United Airlines sees FY22 adjusted CapEx $5.3B
- 04/20/22
- United Airlines sees Q2 capacity down 13% vs 2Q19
- 04/19/22
- DOJ to appeal ruling that lifted COVID mask mandate on travel
- 03/29/22
- United Airlines Ventures, Oxy Low Carbon Ventures partner with Cemvita Factory
- 03/24/22
- Spire Global expands relationship with Slingshot Aerospace
- 03/16/22
- Spire Global announces space-as-a-service agreement with NorthStar Earth & Space
- 03/07/22
- Spire Global, Sierra Nevada announce strategic partnership
- 02/11/22
- Spire Global trading resumes
- 04/22/22
- Snap and Tinuiti enter strategic partnership
- 04/21/22
- Snap says 'really excited' about the Map opportunity
- 04/21/22
- Snap says macroeconomic challenges now 'primary headwinds to client demand'
- 04/21/22
- Snap says 'still early' in realizing monetization potential of content platform
- 04/22/22
- Schlumberger sees outlook for 2H22 'shaping up very well'
- 04/22/22
- Schlumberger reports Q1 cash flow from operations $131M
- 04/22/22
- Schlumberger board approves 40% increase in dividend to 17.5c per share
- 03/19/22
- Schlumberger to immediately suspend new investment in Russia operations
- 02/16/22
- Boston Beer Chairman says 'confident' in FY22 volume growth of 4%-10%
- 02/06/22
- Fly Intel: Top five weekend stock stories
- 01/14/22
- Boston Beer falls -8.7%
- 01/13/22
- Boston Beer falls about 5% after cutting FY21 guidance below $466
- 04/14/22
- Rockley Photonics falls -6.0%
- 03/22/22
- Rockley Photonics falls -9.4%
- 03/22/22
- Rockley Photonics falls -5.3%
- 03/10/22
- Rockley Photonics, Medtronic to enter Bioptx development partnership
- 04/22/22
- Newmont sees FY22 gold production 6.2M ounces
- 04/22/22
- Newmont expects increasing gold production
- 04/21/22
- White Gold reports results of geochemistry surveys on Hayes, Pilot properties
- 04/13/22
- NGM partners with First Solar Technology to decarbonize energy supply
MPW Medical Properties Trust - 04/08/22
- Medical Properties Trust CFO Hamner sells 285,000 common shares
- 04/01/22
- Medical Properties Trust CEO Aldag sells 615,000 common shares
- 02/17/22
- Medical Properties Trust raises quarterly dividend 4% to 29c per share
MIST Milestone Pharmaceuticals - 02/16/22
- Milestone Pharmaceuticals names David Bharucha as Chief Medical Officer
- 11/15/21
- Milestone Pharmaceuticals announces presentation of NODE-301 trial of etripamil
- $138.86 /
+10.86 (+8.48%) - 04/22/22
- Kimberly-Clark rises 9.7%
- 04/22/22
- Kimberly-Clark CEO says taking 'necessary actions to mitigate macro headwinds'
- 04/19/22
- Hasbro appoints Shane Azzi as CSCO, Matt Austin as COO
- 03/22/22
- Kimberly-Clark CFO Maria Henry to retire, Nelson Urdaneta to succeed
- 04/20/22
- Sega says remastered 'Sonic the Hedgehog' collection out June 23, 2022
- 04/20/22
- Ontario Teachers' PPB to invest $175M in KKR's road platform in India
- 04/12/22
- KKR confirms agreement to acquire Barracuda Networks from Thoma Bravo
- 04/11/22
- Sony, Lego holding group invest $2B in Epic Games
- 04/20/22
- JetBlue Technology Ventures makes limited partner investment in TPG Rise Climate
- 04/10/22
- Fly Intel: Top five weekend stock stories
- 04/08/22
- Spirit Airlines to begin discussions with JetBlue
- $253.44 /
-41.255 (-14.00%) - 04/21/22
- Intuitive Surgical raises FY22 procedure growth view to 12%-16% from 11%-15%
- 04/21/22
- Intuitive Surgical says procedure growth in Q1 was 19%
- 01/20/22
- Intuitive Surgical sees FY22 procedure growth 11%-15%
- $209.62 /
-59.7 (-22.17%) - 04/22/22
- HCA Healthcare falls -18.2%
- 04/22/22
- HCA Healthcare falls -13.4%
- 02/14/22
- Appaloosa takes stake in General Motors, exits position in HCA Healthcare
- 01/26/22
- HCA Healthcare to build five new hospitals in Texas
- $11.65 /
-2.635 (-18.45%) - 04/22/22
- Gap falls -17.9%
- 04/22/22
- Gap falls -22.2%
- 04/22/22
- Gap falls -21.2%
- 04/21/22
- Gap falls over 4% to $13.63 after cutting Q1 sales outlook
- 04/22/22
- Ginkgo Bioworks announces partnership with Bayer
- 04/20/22
- Cathie Wood's ARK Investment bought 881K shares of Ginkgo Bioworks today
- 04/18/22
- Cathie Wood's ARK Investment bought 634K shares of Ginkgo Bioworks today
- 04/14/22
- Cathie Wood's ARK Investment bought 794K shares of Ginkgo Bioworks today
- 04/22/22
- Cleveland-Cliffs CEO says 'going to seriously consider' reinstituting dividend
- 04/22/22
- Cleveland-Cliffs rises 9.3%
- 04/22/22
- Cleveland-Cliffs jumps 7% to $31.75 after Q1 results beat estimates
- 04/22/22
- Cleveland-Cliffs raises 2022 average selling price expectation
- 03/04/22
- Chindata appoints Qian Xiao as president, Xinyue Fan as COO
- 02/25/22
- Chindata appoints Huapeng Wu as CEO
- 01/11/22
- Chindata entered into transition agreement with Jing Ju
- 12/06/21
- Chindata to host conference call regarding leadership change
- 04/19/22
- American Campus to be acquired by Blackstone for $65.47 per share in cash
- 03/15/22
- Sanofi, Blackstone announces EUR 300M multiple myeloma collaboration
- 03/14/22
- Blackstone acquires 49% stake in One Manhattan West in deal valued at $2.85B
- 03/01/22
- Blackstone director Porat acquires 5,000 common shares
- 04/22/22
- AB InBev appoints Ricardo Tadeu as CGO
- 04/22/22
- AB InBev plans to sell interest in Russian JV, sees $1.1B impairment charge
- 03/14/22
- Splash Beverage Group expands existing agreement with AB ONE
- 02/24/22
- AB InBev sees FY22 EBITDA in line with 4%-8% medium-term outlook
- $18.23 /
+1.885 (+11.54%) - 04/22/22
- Bed Bath & Beyond trading resumes
- 04/22/22
- Bed Bath & Beyond up 11% after WSJ report on buyout interest for baby unit
- 04/22/22
- Bed Bath & Beyond trading halted, volatility trading pause
- 04/14/22
- Sera Labs products available at Walmart, Bed Bath & Beyond, CVS, Target
- $177.24 /
-3.805 (-2.10%) - 04/19/22
- Gol Linhas signs cargo, logistics services agreement with Mercado Livre
- 04/12/22
- Boeing announces 95 commercial airplane deliveries in Q1
- 04/12/22
- Spirit AeroSystems announces contract from Boeing for B-52 engine replacements
- 04/12/22
- Air Lease announces Q1 activity update
- 04/13/22
- Bread Financial launches new consumer credit card
- 04/01/22
- American Express says 'working diligently' to resolve users' issues with website
- 03/15/22
- American Express reports February net write-off rate 0.9% vs. 0.7% last month
- 03/10/22
- American Express increases quarterly dividend 20% to 52c per share
- 04/22/22
- A10 Networks rises 11.7%
- 04/22/22
- A10 Networks rises 12.1%
- 04/22/22
- A10 Networks rises 12.1%
- 04/21/22
- A10 Networks to replace Ferro in S&P 600 at open on 4/26
- 04/12/22
- American Airlines sees Q1 CASM up 12%-13% vs. 1Q19
- 04/12/22
- XPO appoints David Phalen as SVP, pricing for North American LTL network
- 03/23/22
- JetBlue, American announce 'perks' for TrueBlue Mosaic and AAdvantage members
- 04/22/22 MKM Partners
- United Airlines price target raised to $59 from $53 at MKM Partners
- 04/22/22 Morgan Stanley
- United Airlines price target raised to $67 from $62 at Morgan Stanley
- 04/22/22 Argus
- United Airlines upgraded to Buy from Hold at Argus
- 04/22/22 Cowen
- United Airlines price target raised to $86.50 from $78 at Cowen
- 04/21/22 Raymond James
- Spire Global initiated with an Outperform at Raymond James
- 03/28/22 CJS Securities
- Spire Global initiated with an Outperform at CJS Securities
- 03/03/22 Stifel
- Spire Global initiated with a Buy at Stifel
- 01/19/22 BofA
- Spire Global downgraded to Underperform at BofA on valuation
- 04/19/22 Goldman Sachs
- Ubisoft assumed with Sell from Neutral at Goldman Sachs
- 03/28/22 Jefferies
- Frontier Developments upgraded to Buy from Hold at Jefferies
- 02/22/22 Benchmark
- Ubisoft upgraded to Hold from Sell at Benchmark
- 02/18/22 Barclays
- Ubisoft price target lowered to EUR 47 from EUR 53.20 at Barclays
- 04/22/22 RBC Capital
- Snap price target lowered to $35 from $42 at RBC Capital
- 04/22/22 MKM Partners
- Snap price target lowered to $41 from $47 at MKM Partners
- 04/22/22 Jefferies
- Snap fundamentals intact despite mixed Q1, says Jefferies
- 04/22/22 Evercore ISI
- Snap price target lowered to $47 from $58 at Evercore ISI
- 04/19/22 Northland
- Casa Systems upgraded to Outperform from Market Perform at Northland
- 04/11/22 JPMorgan
- AT&T upgraded to Overweight from Neutral at JPMorgan
- 02/01/22 Citi
- Citi constructive on wireless landscape with T-Mobile top pick
- 01/26/22 Deutsche Bank
- Verizon price target raised to $59 from $57 at Deutsche Bank
- 04/11/22 JPMorgan
- American Express downgraded to Neutral from Overweight at JPMorgan
- 03/28/22 Morgan Stanley
- American Express price target raised to $223 from $218 at Morgan Stanley
- 03/17/22 BofA
- American Express price target raised to $206 from $204 at BofA
- 03/17/22 Morgan Stanley
- American Express positioned for multiple expansion, says Morgan Stanley
- $11.65 /
-2.635 (-18.45%) - 04/22/22 Craig-Hallum
- Land's End downgraded to Hold from Buy at Craig-Hallum
- 04/22/22 B. Riley
- Gap price target lowered to $13 from $15 at B. Riley
- 04/22/22 BMO Capital
- Gap price target lowered to $13 from $16 at BMO Capital
- 04/22/22 Baird
- Gap price target lowered to $14 from $18 at Baird
- 04/20/22 Barclays
- AB InBev price target lowered to EUR 72 from EUR 83 at Barclays
- 04/12/22 Deutsche Bank
- AB InBev price target raised to EUR 75 from EUR 70 at Deutsche Bank
- 04/04/22 RBC Capital
- AB InBev price target raised to EUR 65 from EUR 60 at RBC Capital
- 04/04/22 RBC Capital
- AB InBev price target raised to EUR 65 from EUR 60 at RBC Capital
- 04/22/22 Argus
- American Airlines upgraded to Buy from Hold at Argus
- 04/22/22 JPMorgan
- American Airlines upgraded to Neutral with $26 target at JPMorgan
- 04/22/22 Deutsche Bank
- American Airlines price target raised to $25 from $23 at Deutsche Bank
- 04/22/22 Barclays
- American Airlines price target raised to $20 from $15 at Barclays
- 04/22/22 Deutsche Bank
- JetBlue downgraded to Hold on headwinds at Deutsche Bank
- 04/22/22 Deutsche Bank
- JetBlue downgraded to Hold from Buy at Deutsche Bank
- 04/12/22 Wolfe Research
- JetBlue downgraded to Underperform from Peer Perform at Wolfe Research
- 04/11/22 MKM Partners
- JetBlue upgraded to Neutral at MKM Partners on valuation
MIST Milestone Pharmaceuticals - 04/21/22 Piper Sandler
- Piper upgrades Milestone Pharmaceuticals on etripamil confidence
- 04/21/22 Piper Sandler
- Milestone Pharmaceuticals upgraded to Overweight from Neutral at Piper Sandler
- $177.24 /
-3.805 (-2.10%) - 04/22/22 Benchmark
- Boeing price target lowered to $250 from $270 at Benchmark
- 04/21/22 JPMorgan
- Boeing progress with 787 good news, says JPMorgan
- 04/08/22 Morgan Stanley
- Boeing price target lowered to $230 from $288 at Morgan Stanley
- 03/30/22 Jefferies
- China Southern's 3-year outlook from Boeing down 20 aircraft, says Jefferies
- 03/09/22 Northland
- Rockley Photonics price target lowered to $10 from $20 at Northland
- 03/09/22 Needham
- Rockley Photonics price target lowered to $8 from $15 at Needham
- 12/22/21 BofA
- Rockley Photonics downgraded to Neutral from Buy at BofA
- 12/22/21 BofA
- Rockley Photonics downgraded to Neutral from Buy at BofA
- 04/22/22 BMO Capital
- Blackstone price target raised to $142 from $124 at BMO Capital
- 04/22/22 Deutsche Bank
- Blackstone price target lowered to $182 from $186 at Deutsche Bank
- 04/12/22 Citi
- Blackstone price target lowered to $117 from $132.50 at Citi
- 04/07/22 Deutsche Bank
- Blackstone price target raised to $186 from $180 at Deutsche Bank
- 04/19/22 Wells Fargo
- KKR price target lowered to $73 from $83 at Wells Fargo
- 04/13/22 Oppenheimer
- KKR price target raised to $81 from $76 at Oppenheimer
- 04/13/22 Oppenheimer
- Oppenheimer upgrades Apollo Global following 23% year-to-date pullback
- 04/22/22 Jefferies
- Selloff in China IDC stocks 'significantly overdone,' says Jefferies
- 03/07/22 Credit Suisse
- Chindata upgraded to Outperform from Neutral at Credit Suisse
- 08/18/21
- Fly Intel: Top five analyst initiations
- 08/18/21 JPMorgan
- Chindata initiated with an Overweight at JPMorgan
- 10/29/21 BWS Financial
- A10 Networks price target raised to $20 from $17 at BWS Financial
- 07/28/21 BWS Financial
- A10 Networks price target raised to $17 from $13.50 at BWS Financial
- 06/23/21 Craig-Hallum
- A10 Networks initiated with a Buy at Craig-Hallum
- 06/23/21 Craig-Hallum
- A10 Networks initiated with a Buy at Craig-Hallum
- 03/31/22 BTIG
- Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
- 03/29/22 Cowen
- Ginkgo Bioworks weakness a buying opportunity, says Cowen
- 03/02/22 Cowen
- Ginkgo Bioworks initiated with an Outperform at Cowen
- 02/23/22 Goldman Sachs
- Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
MPW Medical Properties Trust - 04/22/22 Jefferies
- Medical Properties Trust downgraded to Hold at Jefferies on slowing growth
- 04/22/22 Jefferies
- Medical Properties Trust downgraded to Hold from Buy at Jefferies
- 03/11/22 BofA
- Medical Properties Trust downgraded to Neutral from Buy at BofA
- 02/01/22 Credit Suisse
- Medical Properties Trust initiated with an Outperform at Credit Suisse
- 04/20/22 National Bank
- Newmont downgraded to Sector Perform on valuation at National Bank
- 04/19/22 Credit Suisse
- Newmont downgraded to Neutral from Outperform at Credit Suisse
- 03/09/22 Jefferies
- Newmont price target raised to $72 from $67 at Jefferies
- 02/28/22 BofA
- Newmont price target raised to $75 from $70 at BofA
- $209.62 /
-59.7 (-22.17%) - 03/28/22 Wells Fargo
- HCA Healthcare initiated with an Equal Weight at Wells Fargo
- 02/07/22 BofA
- BOFA adds Zoetis and Microsoft to best ideas list, removes two
- 01/31/22 BMO Capital
- HCA Healthcare price target lowered to $250 from $275 at BMO Capital
- 01/31/22 Citi
- HCA Healthcare price target lowered to $277 from $306 at Citi
- 04/22/22 Evercore ISI
- Boston Beer price target lowered to $400 from $600 at Evercore ISI
- 04/22/22 Credit Suisse
- Boston Beer price target lowered to $620 from $670 at Credit Suisse
- 04/22/22 Cowen
- Boston Beer price target lowered to $375 from $500 at Cowen
- 04/22/22 Deutsche Bank
- Boston Beer price target lowered to $337 from $420 at Deutsche Bank
- $253.44 /
-41.255 (-14.00%) - 04/22/22 Evercore ISI
- Intuitive Surgical price target lowered to $280 from $294 at Evercore ISI
- 04/22/22 Raymond James
- Intuitive Surgical price target lowered to $330 from $334 at Raymond James
- 04/22/22 Bernstein
- Bernstein calls Intuitive Surgical 'top pick,' would buy on weakness
- 04/22/22 Piper Sandler
- Intuitive Surgical price target raised to $316 from $310 at Piper Sandler
- 04/19/22 Credit Suisse
- Cleveland-Cliffs price target raised to $37 from $34 at Credit Suisse
- 03/28/22 B. Riley
- Cleveland-Cliffs price target raised to $46 from $37 at B. Riley
- 03/24/22 JPMorgan
- Cleveland-Cliffs price target raised to $44 from $37 at JPMorgan
- 03/15/22 Citi
- Cleveland-Cliffs price target raised to $28 from $25 at Citi
- $138.86 /
+10.86 (+8.48%) - 04/01/22 Barclays
- Kimberly-Clark price target lowered to $121 from $127 at Barclays
- 03/30/22 JPMorgan
- Kimberly-Clark price target lowered to $113 from $118 at JPMorgan
- 03/29/22 Goldman Sachs
- Kimberly-Clark price target lowered to $124 from $130 at Goldman Sachs
- 03/15/22 Wells Fargo
- Kimberly-Clark price target lowered to $128 from $140 at Wells Fargo
- 04/11/22 Piper Sandler
- ChampionX upgraded to Overweight amid higher OFS estimates at Piper Sandler
- 04/11/22 Piper Sandler
- Schlumberger upgraded to Overweight amid higher OFS estimates at Piper Sandler
- 04/11/22 Piper Sandler
- Schlumberger upgraded to Overweight from Neutral at Piper Sandler
- 04/08/22 Stifel
- Schlumberger price target raised to $50 from $44 at Stifel
- $18.23 /
+1.885 (+11.54%) - 04/14/22 Telsey Advisory
- Bed Bath & Beyond downgraded to Underperform at Telsey Advisory
- 04/14/22 B. Riley
- Bed Bath & Beyond shares still offer value, says B. Riley
- 04/13/22 Wells Fargo
- Wells Fargo halves Bed Bath & Beyond target, says take profits today
- 04/13/22 Wells Fargo
- Bed Bath & Beyond price target lowered to $10 from $20 at Wells Fargo
- 04/22/22
- Verizon sees 2022 adjusted EPS at lower end of $5.40-$5.55, consensus $5.45
- 04/22/22
- Verizon reports Q1 adjusted EPS $1.35, consensus $1.34
- 01/25/22
- Verizon sees 2022 adjusted EPS $5.40-$5.55, consensus $5.39
- 01/25/22
- Verizon reports Q4 adjusted EPS $1.31, consensus $1.29
- 02/17/22
- Ubisoft backs FY21-22 net bookings target of flat to slightly down
- 02/17/22
- Ubisoft reports Q3 net bookings EUR746.1M, in line with target range
- 10/28/21
- Ubisoft backs FY22 non-IFRS operating income view of EUR420M-EUR500M
- 10/28/21
- Ubisoft sees Q3 net bookings EUR725M-EUR780M
- 04/20/22
- United Airlines reports Q1 adjusted EPS ($4.24), consensus ($4.21)
- 04/20/22
- Notable companies reporting after market close
- 03/15/22
- United Airlines sees Q1 capacity down approximately 19%
- 01/19/22
- United Airlines sees FY22 capacity down vs 2019
- 03/09/22
- Spire Global sees FY22 adjusted EPS (44c)-(41c), consensus (39c)
- 03/09/22
- Spire Global sees Q1 adjusted EPS (14c)-(13c), consensus (11c)
- 03/09/22
- Spire Global reports preliminary Q4 EPS 38c, consensus (13c)
- 01/31/22
- Spire Global sees FY22 revenue $85M-$90M, consensus $72.3M
- 04/21/22
- Snap sees Q2 revenue up 20%-25% y/y, consensus $1.26B
- 04/21/22
- Snap reports Q1 EPS (2c), consensus 1c
- 04/21/22
- Notable companies reporting after market close
- 02/03/22
- Snap sees Q1 revenue $1.03B-$1.08B, consensus $1.02B
- 04/22/22
- Schlumberger CEO says 'firmly on path' to FY revenue growth in mid-teens
- 04/22/22
- Schlumberger reports Q1 adjusted EPS 34c, consensus 30c
- 03/08/22
- Schlumberger sees overall 2022 revenue growth to reach mid-teens percentage
- 01/21/22
- Schlumberger reports Q4 adjusted EPS 41c, consensus 34c
- 04/21/22
- Boston Beer sees FY22 non-GAAP EPS $11.00-$16.00, consensus $13.85
- 04/21/22
- Boston Beer reports Q1 EPS (16c), consensus $1.97
- 02/16/22
- Boston Beer sees FY22 adjusted EPS $11.00-$16.00, consensus $16.13
- 02/16/22
- Boston Beer reports Q4 EPS ($4.22), consensus ($3.23)
- 03/08/22
- Rockley Photonics sees FY22 revenue $20M-$30M, consensus $24.87M
- 03/08/22
- Rockley Photonics reports Q4 adjusted EPS (6c), consensus (33c)
- 12/21/21
- Rockley Photonics sees FY22 revenue $25M-$30M, consensus $59.1M
- 11/15/21
- Rockley Photonics reports Q3 EPS (48c), consensus (20c)
- 04/22/22
- Newmont reports Q1 EPS 56c, consensus 89c
- 02/24/22
- Newmont reports Q4 adjusted EPS 78c, consensus 99c
- 10/28/21
- Newmont reports Q3 EPS 60c versus 86c in Q320
MPW Medical Properties Trust - 02/03/22
- Medical Properties Trust sees FY22 normalized FFO $1.81-$1.85, consensus $1.90
- 02/03/22
- Medical Properties Trust reports Q4 normalized FFO 47c, consensus 46c
- 10/28/21
- Medical Properties Trust sees FY21 normalized FFO $1.81-$1.85, consensus $1.75
- 10/28/21
- Medical Properties Trust reports Q3 normalized FFO 44c, consensus 44c
MIST Milestone Pharmaceuticals - 03/24/22
- Milestone Pharmaceuticals reports Q4 EPS (40c), consensus (36c)
- 11/12/21
- Milestone Pharmaceuticals reports Q3 EPS (34c), consensus (38c)
- $138.86 /
+10.86 (+8.48%) - 04/22/22
- Kimberly-Clark raises FY22 revenue growth view to 2%-4% from 1%-2%
- 04/22/22
- Kimberly-Clark backs FY22 adjusted EPS view $5.60-$6.00, consensus $5.75
- 04/22/22
- Kimberly-Clark reports Q1 adjusted EPS $1.35, consensus $1.23
- 01/26/22
- Kimberly-Clark sees FY22 EPS $5.60-$6.00, consensus $6.70
- 02/08/22
- KKR reports Q4 EPS 82c vs. $2.46 last year
- 02/07/22
- Notable companies reporting before tomorrow's open
- 11/02/21
- KKR reports Q3 GAAP EPS $1.80 vs. $1.79 a year ago
- 01/27/22
- JetBlue sees Q1 revenue down 11%-16%
- 01/27/22
- JetBlue reports Q4 EPS (36c), consensus (39c)
- 01/26/22
- Notable companies reporting before tomorrow's open
- $253.44 /
-41.255 (-14.00%) - 04/21/22
- Intuitive Surgical reports Q1 EPS $1.13, consensus $1.08
- 01/20/22
- Intuitive Surgical reports Q4 EPS $1.30, consensus $1.28
- 01/20/22
- Notable companies reporting after market close
- $209.62 /
-59.7 (-22.17%) - 04/22/22
- HCA Healthcare cuts FY22 EPS view to $16.40-$17.60 from $18.40-$19.20
- 04/22/22
- HCA Healthcare reports Q1 EPS $4.14, consensus $4.25
- 01/27/22
- HCA Healthcare sees FY22 EPS $18.40-$19.20, consensus $18.73
- 01/27/22
- HCA Healthcare reports Q4 EPS $5.75, consensus $4.53
- $11.65 /
-2.635 (-18.45%) - 03/03/22
- Gap sees FY22 adjusted EPS $1.85-$2.05, consensus $1.86
- 03/03/22
- Gap reports Q4 adjusted EPS (2c), consensus (14c)
- 03/03/22
- Notable companies reporting after market close
- 11/23/21
- Gap reports Q3 Old Navy SSS down 9% y/y
- 03/28/22
- Ginkgo Bioworks sees FY22 revenue $325M-$340M, consensus $305.75M
- 03/28/22
- Ginkgo Bioworks reports Q4 EPS ($1.10), consensus (4c)
- 01/12/22
- Ginkgo Bioworks sees 2021 revenue above guidance
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
- 04/22/22
- Cleveland-Cliffs reports Q1 EPS $1.50, consensus $1.40
- 02/11/22
- Cleveland-Cliffs reports Q4 EPS $1.69, consensus $2.12
- 03/10/22
- Chindata sees FY21 revenue up 42.7%-46.2% y-o-y to RMB4.07B-RMB4.17B
- 03/10/22
- Chindata reports Q4 EPS 3c, consensus 1c
- 11/24/21
- Chindata backs FY21 revenue growth 51.8%-54.6%, consensus $439.43M
- 11/24/21
- Chindata reports Q3 EPS 2c, consensus (3c)
- 01/27/22
- Blackstone reports Q4 distributable EPS $1.71, consensus $1.37
- 02/24/22
- AB InBev reports Q4 normalized EPS 90c, consensus 76c
- 10/28/21
- AB InBev reports Q3 normalized EPS 79c, consenus 66c
- 10/27/21
- Notable companies reporting before tomorrow's open
- $18.23 /
+1.885 (+11.54%) - 04/13/22
- Bed Bath & Beyond reports Q4 adjusted EPS (92c), consensus 3c
- 04/12/22
- Notable companies reporting before tomorrow's open
- 01/06/22
- Bed Bath & Beyond cuts FY21 adjusted EPS view to (15c)-0c from 70c-$1.10
- $177.24 /
-3.805 (-2.10%) - 04/11/22
- Ultra Clean cuts Q1 revenue view to $560M-$570M from $580M-$630M
- 01/26/22
- Boeing reports Q4 core EPS ($7.69), consensus (30c)
- 01/25/22
- Notable companies reporting before tomorrow's open
- 04/22/22
- American Express reports Q1 EPS $2.73, consensus $2.44
- 02/27/22
- Berkshire operating earnings surge, Buffett repurchases record $27B in stock
- 01/25/22
- American Express sees FY22 EPS $9.25-$9.65, consensus $9.67
- 01/25/22
- American Express reports Q4 EPS $2.18, consensus $1.87
- 02/01/22
- A10 Networks sees FY22 revenue growth of 10%-12%
- 02/01/22
- A10 Networks sees Q1 revenue growth of 10%-12%
- 02/01/22
- A10 Networks reports Q4 EPS 20c, two estimates 17c
- 10/28/21
- A10 Networks sees Q4 revenue up 10% y/y, consensus $66.73M
- 04/21/22
- American Airlines sees Q2 revenue up 6%-8% vs. last year, consensus $11.26B
- 04/21/22
- American Airlines reports Q1 EPS ex-items ($2.32), consensus ($2.40)
- 04/20/22
- Notable companies reporting before tomorrow's open
|
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 04/22/22
- Verizon reports Q1 Consumer wireless retail postpaid net losses of 292K
- 04/22/22
- Verizon reports Q1 Business retail postpaid net additions 395K
- 04/22/22
- Verizon reports Q1 Broadband net additions 229,000
- 04/22/22
- Verizon CFO says results show 'strength of core business'
- 04/20/22
- United Airlines sees FY22 adjusted CapEx $5.3B
- 04/20/22
- United Airlines sees Q2 capacity down 13% vs 2Q19
- 04/19/22
- DOJ to appeal ruling that lifted COVID mask mandate on travel
- 03/29/22
- United Airlines Ventures, Oxy Low Carbon Ventures partner with Cemvita Factory
- 03/24/22
- Spire Global expands relationship with Slingshot Aerospace
- 03/16/22
- Spire Global announces space-as-a-service agreement with NorthStar Earth & Space
- 03/07/22
- Spire Global, Sierra Nevada announce strategic partnership
- 02/11/22
- Spire Global trading resumes
- 04/22/22
- Snap and Tinuiti enter strategic partnership
- 04/21/22
- Snap says 'really excited' about the Map opportunity
- 04/21/22
- Snap says macroeconomic challenges now 'primary headwinds to client demand'
- 04/21/22
- Snap says 'still early' in realizing monetization potential of content platform
- 04/22/22
- Schlumberger sees outlook for 2H22 'shaping up very well'
- 04/22/22
- Schlumberger reports Q1 cash flow from operations $131M
- 04/22/22
- Schlumberger board approves 40% increase in dividend to 17.5c per share
- 03/19/22
- Schlumberger to immediately suspend new investment in Russia operations
- 02/16/22
- Boston Beer Chairman says 'confident' in FY22 volume growth of 4%-10%
- 02/06/22
- Fly Intel: Top five weekend stock stories
- 01/14/22
- Boston Beer falls -8.7%
- 01/13/22
- Boston Beer falls about 5% after cutting FY21 guidance below $466
- 01/27/22
- Renault-Nissan alliance plans EUR 23B investment in electric cars
- 04/14/22
- Rockley Photonics falls -6.0%
- 03/22/22
- Rockley Photonics falls -9.4%
- 03/22/22
- Rockley Photonics falls -5.3%
- 03/10/22
- Rockley Photonics, Medtronic to enter Bioptx development partnership
- 04/13/22
- Ferrari announces results from Annual General Meeting
- 03/22/22
- Ferrari announces MoU with Italian intitutions for investments in technology
- 02/08/22
- Ferrari, Qualcomm announce new technology partnership
- 01/10/22
- Ferrari unveils new organizational structure
- 04/22/22
- Newmont sees FY22 gold production 6.2M ounces
- 04/22/22
- Newmont expects increasing gold production
- 04/21/22
- White Gold reports results of geochemistry surveys on Hayes, Pilot properties
- 04/13/22
- NGM partners with First Solar Technology to decarbonize energy supply
MPW Medical Properties Trust - 04/08/22
- Medical Properties Trust CFO Hamner sells 285,000 common shares
- 04/01/22
- Medical Properties Trust CEO Aldag sells 615,000 common shares
- 02/17/22
- Medical Properties Trust raises quarterly dividend 4% to 29c per share
MIST Milestone Pharmaceuticals - 02/16/22
- Milestone Pharmaceuticals names David Bharucha as Chief Medical Officer
- 11/15/21
- Milestone Pharmaceuticals announces presentation of NODE-301 trial of etripamil
- $140.11 /
+12.11 (+9.46%) - 04/22/22
- Kimberly-Clark rises 9.7%
- 04/22/22
- Kimberly-Clark CEO says taking 'necessary actions to mitigate macro headwinds'
- 04/19/22
- Hasbro appoints Shane Azzi as CSCO, Matt Austin as COO
- 03/22/22
- Kimberly-Clark CFO Maria Henry to retire, Nelson Urdaneta to succeed
- 04/20/22
- JetBlue Technology Ventures makes limited partner investment in TPG Rise Climate
- 04/10/22
- Fly Intel: Top five weekend stock stories
- 04/08/22
- Spirit Airlines to begin discussions with JetBlue
- $258.22 /
-36.475 (-12.38%) - 04/21/22
- Intuitive Surgical raises FY22 procedure growth view to 12%-16% from 11%-15%
- 04/21/22
- Intuitive Surgical says procedure growth in Q1 was 19%
- 01/20/22
- Intuitive Surgical sees FY22 procedure growth 11%-15%
- $219.82 /
-49.5 (-18.38%) - 04/22/22
- HCA Healthcare falls -18.2%
- 04/22/22
- HCA Healthcare falls -13.4%
- 02/14/22
- Appaloosa takes stake in General Motors, exits position in HCA Healthcare
- 01/26/22
- HCA Healthcare to build five new hospitals in Texas
- $11.73 /
-2.555 (-17.89%) - 04/22/22
- Gap falls -17.9%
- 04/22/22
- Gap falls -22.2%
- 04/22/22
- Gap falls -21.2%
- 04/21/22
- Gap falls over 4% to $13.63 after cutting Q1 sales outlook
- 04/22/22
- Ginkgo Bioworks announces partnership with Bayer
- 04/20/22
- Cathie Wood's ARK Investment bought 881K shares of Ginkgo Bioworks today
- 04/18/22
- Cathie Wood's ARK Investment bought 634K shares of Ginkgo Bioworks today
- 04/14/22
- Cathie Wood's ARK Investment bought 794K shares of Ginkgo Bioworks today
- 04/22/22
- Cleveland-Cliffs CEO says 'going to seriously consider' reinstituting dividend
- 04/22/22
- Cleveland-Cliffs rises 9.3%
- 04/22/22
- Cleveland-Cliffs jumps 7% to $31.75 after Q1 results beat estimates
- 04/22/22
- Cleveland-Cliffs raises 2022 average selling price expectation
- 03/04/22
- Chindata appoints Qian Xiao as president, Xinyue Fan as COO
- 02/25/22
- Chindata appoints Huapeng Wu as CEO
- 01/11/22
- Chindata entered into transition agreement with Jing Ju
- 12/06/21
- Chindata to host conference call regarding leadership change
- 04/22/22
- AB InBev appoints Ricardo Tadeu as CGO
- 04/22/22
- AB InBev plans to sell interest in Russian JV, sees $1.1B impairment charge
- 03/14/22
- Splash Beverage Group expands existing agreement with AB ONE
- 02/24/22
- AB InBev sees FY22 EBITDA in line with 4%-8% medium-term outlook
- 04/13/22
- Bread Financial launches new consumer credit card
- 04/01/22
- American Express says 'working diligently' to resolve users' issues with website
- 03/15/22
- American Express reports February net write-off rate 0.9% vs. 0.7% last month
- 03/10/22
- American Express increases quarterly dividend 20% to 52c per share
- 04/22/22
- A10 Networks rises 11.7%
- 04/22/22
- A10 Networks rises 12.1%
- 04/22/22
- A10 Networks rises 12.1%
- 04/21/22
- A10 Networks to replace Ferro in S&P 600 at open on 4/26
- $2,924.35 /
-43.11 (-1.45%) - 04/21/22
- Amazon creates $1B venture fund for fulfillment, logistics and supply chain
- 04/21/22
- Amazon Web Services announces general availability of Aurora Serverless v2
- 04/21/22
- Amazon Web Services announces general availability of AWS Amplify Studio
- 04/21/22
- AppLovin announces Christina Seafort joins as Chief People Officer
- 04/12/22
- American Airlines sees Q1 CASM up 12%-13% vs. 1Q19
- 04/12/22
- XPO appoints David Phalen as SVP, pricing for North American LTL network
- 03/23/22
- JetBlue, American announce 'perks' for TrueBlue Mosaic and AAdvantage members
- 04/22/22 RBC Capital
- Snap price target lowered to $35 from $42 at RBC Capital
- 04/22/22 MKM Partners
- Snap price target lowered to $41 from $47 at MKM Partners
- 04/22/22 Jefferies
- Snap fundamentals intact despite mixed Q1, says Jefferies
- 04/22/22 Evercore ISI
- Snap price target lowered to $47 from $58 at Evercore ISI
- 04/19/22 Northland
- Casa Systems upgraded to Outperform from Market Perform at Northland
- 04/11/22 JPMorgan
- AT&T upgraded to Overweight from Neutral at JPMorgan
- 02/01/22 Citi
- Citi constructive on wireless landscape with T-Mobile top pick
- 01/26/22 Deutsche Bank
- Verizon price target raised to $59 from $57 at Deutsche Bank
- 04/11/22 JPMorgan
- American Express downgraded to Neutral from Overweight at JPMorgan
- 03/28/22 Morgan Stanley
- American Express price target raised to $223 from $218 at Morgan Stanley
- 03/17/22 BofA
- American Express price target raised to $206 from $204 at BofA
- 03/17/22 Morgan Stanley
- American Express positioned for multiple expansion, says Morgan Stanley
- $11.73 /
-2.555 (-17.89%) - 04/22/22 Craig-Hallum
- Land's End downgraded to Hold from Buy at Craig-Hallum
- 04/22/22 B. Riley
- Gap price target lowered to $13 from $15 at B. Riley
- 04/22/22 BMO Capital
- Gap price target lowered to $13 from $16 at BMO Capital
- 04/22/22 Baird
- Gap price target lowered to $14 from $18 at Baird
- 04/20/22 Barclays
- AB InBev price target lowered to EUR 72 from EUR 83 at Barclays
- 04/12/22 Deutsche Bank
- AB InBev price target raised to EUR 75 from EUR 70 at Deutsche Bank
- 04/04/22 RBC Capital
- AB InBev price target raised to EUR 65 from EUR 60 at RBC Capital
- 04/04/22 RBC Capital
- AB InBev price target raised to EUR 65 from EUR 60 at RBC Capital
- 03/09/22 Northland
- Rockley Photonics price target lowered to $10 from $20 at Northland
- 03/09/22 Needham
- Rockley Photonics price target lowered to $8 from $15 at Needham
- 12/22/21 BofA
- Rockley Photonics downgraded to Neutral from Buy at BofA
- 12/22/21 BofA
- Rockley Photonics downgraded to Neutral from Buy at BofA
- 04/19/22 UBS
- Renault price target lowered to EUR 40 from EUR 49 at UBS
- 04/14/22 Barclays
- Renault price target lowered to EUR 25 from EUR 33 at Barclays
- 04/06/22 JPMorgan
- Renault price target lowered to EUR 55 from EUR 62 at JPMorgan
- 03/31/22 Deutsche Bank
- Renault price target lowered to EUR 35 from EUR 40 at Deutsche Bank
- 04/22/22 Jefferies
- Selloff in China IDC stocks 'significantly overdone,' says Jefferies
- 03/07/22 Credit Suisse
- Chindata upgraded to Outperform from Neutral at Credit Suisse
- 08/18/21
- Fly Intel: Top five analyst initiations
- 08/18/21 JPMorgan
- Chindata initiated with an Overweight at JPMorgan
- $2,924.35 /
-43.11 (-1.45%) - 04/22/22 Credit Suisse
- Amazon.com remains top pick at Credit Suisse ahead of Q1 report
- 04/21/22 Wedbush
- Wedbush expects Amazon to benefit from robust consumer demand
- 04/20/22 UBS
- Amazon.com price target lowered to $4,550 from $4,625 at UBS
- 04/20/22 MKM Partners
- Amazon.com price target lowered to $4,000 from $4,100 at MKM Partners
- 04/12/22 Exane BNP Paribas
- Ferrari upgraded to Outperform from Neutral at Exane BNP Paribas
- 04/04/22 UBS
- Ferrari price target raised to $263 from $260 at UBS
- 02/03/22 Morgan Stanley
- Rivian preferred over Lucid by 87% of surveyed investors, says Morgan Stanley
- 02/03/22 UBS
- Ferrari price target lowered to $277 from $305 at UBS
- 04/22/22 Evercore ISI
- Boston Beer price target lowered to $400 from $600 at Evercore ISI
- 04/22/22 Credit Suisse
- Boston Beer price target lowered to $620 from $670 at Credit Suisse
- 04/22/22 Cowen
- Boston Beer price target lowered to $375 from $500 at Cowen
- 04/22/22 Deutsche Bank
- Boston Beer price target lowered to $337 from $420 at Deutsche Bank
- $258.22 /
-36.475 (-12.38%) - 04/22/22 Evercore ISI
- Intuitive Surgical price target lowered to $280 from $294 at Evercore ISI
- 04/22/22 Raymond James
- Intuitive Surgical price target lowered to $330 from $334 at Raymond James
- 04/22/22 Bernstein
- Bernstein calls Intuitive Surgical 'top pick,' would buy on weakness
- 04/22/22 Piper Sandler
- Intuitive Surgical price target raised to $316 from $310 at Piper Sandler
- 04/19/22 Credit Suisse
- Cleveland-Cliffs price target raised to $37 from $34 at Credit Suisse
- 03/28/22 B. Riley
- Cleveland-Cliffs price target raised to $46 from $37 at B. Riley
- 03/24/22 JPMorgan
- Cleveland-Cliffs price target raised to $44 from $37 at JPMorgan
- 03/15/22 Citi
- Cleveland-Cliffs price target raised to $28 from $25 at Citi
- $140.11 /
+12.11 (+9.46%) - 04/01/22 Barclays
- Kimberly-Clark price target lowered to $121 from $127 at Barclays
- 03/30/22 JPMorgan
- Kimberly-Clark price target lowered to $113 from $118 at JPMorgan
- 03/29/22 Goldman Sachs
- Kimberly-Clark price target lowered to $124 from $130 at Goldman Sachs
- 03/15/22 Wells Fargo
- Kimberly-Clark price target lowered to $128 from $140 at Wells Fargo
- $219.82 /
-49.5 (-18.38%) - 03/28/22 Wells Fargo
- HCA Healthcare initiated with an Equal Weight at Wells Fargo
- 02/07/22 BofA
- BOFA adds Zoetis and Microsoft to best ideas list, removes two
- 01/31/22 BMO Capital
- HCA Healthcare price target lowered to $250 from $275 at BMO Capital
- 01/31/22 Citi
- HCA Healthcare price target lowered to $277 from $306 at Citi
- 04/11/22 Piper Sandler
- ChampionX upgraded to Overweight amid higher OFS estimates at Piper Sandler
- 04/11/22 Piper Sandler
- Schlumberger upgraded to Overweight amid higher OFS estimates at Piper Sandler
- 04/11/22 Piper Sandler
- Schlumberger upgraded to Overweight from Neutral at Piper Sandler
- 04/08/22 Stifel
- Schlumberger price target raised to $50 from $44 at Stifel
- 10/29/21 BWS Financial
- A10 Networks price target raised to $20 from $17 at BWS Financial
- 07/28/21 BWS Financial
- A10 Networks price target raised to $17 from $13.50 at BWS Financial
- 06/23/21 Craig-Hallum
- A10 Networks initiated with a Buy at Craig-Hallum
- 06/23/21 Craig-Hallum
- A10 Networks initiated with a Buy at Craig-Hallum
- 03/31/22 BTIG
- Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
- 03/29/22 Cowen
- Ginkgo Bioworks weakness a buying opportunity, says Cowen
- 03/02/22 Cowen
- Ginkgo Bioworks initiated with an Outperform at Cowen
- 02/23/22 Goldman Sachs
- Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
MPW Medical Properties Trust - 04/22/22 Jefferies
- Medical Properties Trust downgraded to Hold at Jefferies on slowing growth
- 04/22/22 Jefferies
- Medical Properties Trust downgraded to Hold from Buy at Jefferies
- 03/11/22 BofA
- Medical Properties Trust downgraded to Neutral from Buy at BofA
- 02/01/22 Credit Suisse
- Medical Properties Trust initiated with an Outperform at Credit Suisse
- 04/20/22 National Bank
- Newmont downgraded to Sector Perform on valuation at National Bank
- 04/19/22 Credit Suisse
- Newmont downgraded to Neutral from Outperform at Credit Suisse
- 03/09/22 Jefferies
- Newmont price target raised to $72 from $67 at Jefferies
- 02/28/22 BofA
- Newmont price target raised to $75 from $70 at BofA
- 04/22/22 MKM Partners
- United Airlines price target raised to $59 from $53 at MKM Partners
- 04/22/22 Morgan Stanley
- United Airlines price target raised to $67 from $62 at Morgan Stanley
- 04/22/22 Argus
- United Airlines upgraded to Buy from Hold at Argus
- 04/22/22 Cowen
- United Airlines price target raised to $86.50 from $78 at Cowen
- 04/22/22 Argus
- American Airlines upgraded to Buy from Hold at Argus
- 04/22/22 JPMorgan
- American Airlines upgraded to Neutral with $26 target at JPMorgan
- 04/22/22 Deutsche Bank
- American Airlines price target raised to $25 from $23 at Deutsche Bank
- 04/22/22 Barclays
- American Airlines price target raised to $20 from $15 at Barclays
- 04/22/22 Deutsche Bank
- JetBlue downgraded to Hold on headwinds at Deutsche Bank
- 04/22/22 Deutsche Bank
- JetBlue downgraded to Hold from Buy at Deutsche Bank
- 04/12/22 Wolfe Research
- JetBlue downgraded to Underperform from Peer Perform at Wolfe Research
- 04/11/22 MKM Partners
- JetBlue upgraded to Neutral at MKM Partners on valuation
MIST Milestone Pharmaceuticals - 04/21/22 Piper Sandler
- Piper upgrades Milestone Pharmaceuticals on etripamil confidence
- 04/21/22 Piper Sandler
- Milestone Pharmaceuticals upgraded to Overweight from Neutral at Piper Sandler
- 04/21/22 Raymond James
- Spire Global initiated with an Outperform at Raymond James
- 03/28/22 CJS Securities
- Spire Global initiated with an Outperform at CJS Securities
- 03/03/22 Stifel
- Spire Global initiated with a Buy at Stifel
- 01/19/22 BofA
- Spire Global downgraded to Underperform at BofA on valuation
- 04/22/22
- Verizon sees 2022 adjusted EPS at lower end of $5.40-$5.55, consensus $5.45
- 04/22/22
- Verizon reports Q1 adjusted EPS $1.35, consensus $1.34
- 01/25/22
- Verizon sees 2022 adjusted EPS $5.40-$5.55, consensus $5.39
- 01/25/22
- Verizon reports Q4 adjusted EPS $1.31, consensus $1.29
- 04/20/22
- United Airlines reports Q1 adjusted EPS ($4.24), consensus ($4.21)
- 04/20/22
- Notable companies reporting after market close
- 03/15/22
- United Airlines sees Q1 capacity down approximately 19%
- 01/19/22
- United Airlines sees FY22 capacity down vs 2019
- 03/09/22
- Spire Global sees FY22 adjusted EPS (44c)-(41c), consensus (39c)
- 03/09/22
- Spire Global sees Q1 adjusted EPS (14c)-(13c), consensus (11c)
- 03/09/22
- Spire Global reports preliminary Q4 EPS 38c, consensus (13c)
- 01/31/22
- Spire Global sees FY22 revenue $85M-$90M, consensus $72.3M
- 04/21/22
- Snap sees Q2 revenue up 20%-25% y/y, consensus $1.26B
- 04/21/22
- Snap reports Q1 EPS (2c), consensus 1c
- 04/21/22
- Notable companies reporting after market close
- 02/03/22
- Snap sees Q1 revenue $1.03B-$1.08B, consensus $1.02B
- 04/22/22
- Schlumberger CEO says 'firmly on path' to FY revenue growth in mid-teens
- 04/22/22
- Schlumberger reports Q1 adjusted EPS 34c, consensus 30c
- 03/08/22
- Schlumberger sees overall 2022 revenue growth to reach mid-teens percentage
- 01/21/22
- Schlumberger reports Q4 adjusted EPS 41c, consensus 34c
- 04/21/22
- Boston Beer sees FY22 non-GAAP EPS $11.00-$16.00, consensus $13.85
- 04/21/22
- Boston Beer reports Q1 EPS (16c), consensus $1.97
- 02/16/22
- Boston Beer sees FY22 adjusted EPS $11.00-$16.00, consensus $16.13
- 02/16/22
- Boston Beer reports Q4 EPS ($4.22), consensus ($3.23)
- 03/08/22
- Rockley Photonics sees FY22 revenue $20M-$30M, consensus $24.87M
- 03/08/22
- Rockley Photonics reports Q4 adjusted EPS (6c), consensus (33c)
- 12/21/21
- Rockley Photonics sees FY22 revenue $25M-$30M, consensus $59.1M
- 11/15/21
- Rockley Photonics reports Q3 EPS (48c), consensus (20c)
- 02/02/22
- Ferrari sees FY22 EPS EUR 4.55-4.75 vs. EUR 4.50 in FY21
- 02/02/22
- Ferrari reports Q4 adjuated EPS EUR 1.16 vs. EUR 1.01 last year
- 11/02/21
- Ferrari sees 2021 net revenues GBP4.3B
- 11/02/21
- Ferrari reports Q3 adjuste EPS EUR 1.11 vs. EUR 0.92 last year
- 04/22/22
- Newmont reports Q1 EPS 56c, consensus 89c
- 02/24/22
- Newmont reports Q4 adjusted EPS 78c, consensus 99c
- 10/28/21
- Newmont reports Q3 EPS 60c versus 86c in Q320
MPW Medical Properties Trust - 02/03/22
- Medical Properties Trust sees FY22 normalized FFO $1.81-$1.85, consensus $1.90
- 02/03/22
- Medical Properties Trust reports Q4 normalized FFO 47c, consensus 46c
- 10/28/21
- Medical Properties Trust sees FY21 normalized FFO $1.81-$1.85, consensus $1.75
- 10/28/21
- Medical Properties Trust reports Q3 normalized FFO 44c, consensus 44c
MIST Milestone Pharmaceuticals - 03/24/22
- Milestone Pharmaceuticals reports Q4 EPS (40c), consensus (36c)
- 11/12/21
- Milestone Pharmaceuticals reports Q3 EPS (34c), consensus (38c)
- $140.11 /
+12.11 (+9.46%) - 04/22/22
- Kimberly-Clark raises FY22 revenue growth view to 2%-4% from 1%-2%
- 04/22/22
- Kimberly-Clark backs FY22 adjusted EPS view $5.60-$6.00, consensus $5.75
- 04/22/22
- Kimberly-Clark reports Q1 adjusted EPS $1.35, consensus $1.23
- 01/26/22
- Kimberly-Clark sees FY22 EPS $5.60-$6.00, consensus $6.70
- 01/27/22
- JetBlue sees Q1 revenue down 11%-16%
- 01/27/22
- JetBlue reports Q4 EPS (36c), consensus (39c)
- 01/26/22
- Notable companies reporting before tomorrow's open
- $258.22 /
-36.475 (-12.38%) - 04/21/22
- Intuitive Surgical reports Q1 EPS $1.13, consensus $1.08
- 01/20/22
- Intuitive Surgical reports Q4 EPS $1.30, consensus $1.28
- 01/20/22
- Notable companies reporting after market close
- $219.82 /
-49.5 (-18.38%) - 04/22/22
- HCA Healthcare cuts FY22 EPS view to $16.40-$17.60 from $18.40-$19.20
- 04/22/22
- HCA Healthcare reports Q1 EPS $4.14, consensus $4.25
- 01/27/22
- HCA Healthcare sees FY22 EPS $18.40-$19.20, consensus $18.73
- 01/27/22
- HCA Healthcare reports Q4 EPS $5.75, consensus $4.53
- $11.73 /
-2.555 (-17.89%) - 03/03/22
- Gap sees FY22 adjusted EPS $1.85-$2.05, consensus $1.86
- 03/03/22
- Gap reports Q4 adjusted EPS (2c), consensus (14c)
- 03/03/22
- Notable companies reporting after market close
- 11/23/21
- Gap reports Q3 Old Navy SSS down 9% y/y
- 03/28/22
- Ginkgo Bioworks sees FY22 revenue $325M-$340M, consensus $305.75M
- 03/28/22
- Ginkgo Bioworks reports Q4 EPS ($1.10), consensus (4c)
- 01/12/22
- Ginkgo Bioworks sees 2021 revenue above guidance
- 11/15/21
- Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c)
- 04/22/22
- Cleveland-Cliffs reports Q1 EPS $1.50, consensus $1.40
- 02/11/22
- Cleveland-Cliffs reports Q4 EPS $1.69, consensus $2.12
- 03/10/22
- Chindata sees FY21 revenue up 42.7%-46.2% y-o-y to RMB4.07B-RMB4.17B
- 03/10/22
- Chindata reports Q4 EPS 3c, consensus 1c
- 11/24/21
- Chindata backs FY21 revenue growth 51.8%-54.6%, consensus $439.43M
- 11/24/21
- Chindata reports Q3 EPS 2c, consensus (3c)
- 02/24/22
- AB InBev reports Q4 normalized EPS 90c, consensus 76c
- 10/28/21
- AB InBev reports Q3 normalized EPS 79c, consenus 66c
- 10/27/21
- Notable companies reporting before tomorrow's open
- 04/22/22
- American Express reports Q1 EPS $2.73, consensus $2.44
- 02/27/22
- Berkshire operating earnings surge, Buffett repurchases record $27B in stock
- 01/25/22
- American Express sees FY22 EPS $9.25-$9.65, consensus $9.67
- 01/25/22
- American Express reports Q4 EPS $2.18, consensus $1.87
- 02/01/22
- A10 Networks sees FY22 revenue growth of 10%-12%
- 02/01/22
- A10 Networks sees Q1 revenue growth of 10%-12%
- 02/01/22
- A10 Networks reports Q4 EPS 20c, two estimates 17c
- 10/28/21
- A10 Networks sees Q4 revenue up 10% y/y, consensus $66.73M
- $2,924.35 /
-43.11 (-1.45%) - 02/03/22
- Amazon sees Q1 revenue $112B-$117B, consensus $120.11B
- 02/03/22
- Amazon reports Q4 EPS $27.75 with gains vs. $14.09 a year ago
- 02/03/22
- Notable companies reporting after market close
- 11/10/21
- Affirm sees fiscal 2022 revenue $1.225B-$1.25B, consensus $1.20B
- 04/21/22
- American Airlines sees Q2 revenue up 6%-8% vs. last year, consensus $11.26B
- 04/21/22
- American Airlines reports Q1 EPS ex-items ($2.32), consensus ($2.40)
- 04/20/22
- Notable companies reporting before tomorrow's open
|
|
On The Fly
| ShowHide Related Items >><< - 04/21/22
- Union Pacific CEO: 'Operationally, we did not meet expectations'
- 04/21/22
- Union Pacific backs FY22 CapEx view $3.3B
- 04/21/22
- Union Pacific revises FY22 operating ratio to 'beginning with 55'
- 04/21/22
- Union Pacific reports Q1 operating ratio 59.4%, up 70 bps y/y
- 04/20/22
- United Airlines sees FY22 adjusted CapEx $5.3B
- 04/20/22
- United Airlines sees Q2 capacity down 13% vs 2Q19
- 04/19/22
- DOJ to appeal ruling that lifted COVID mask mandate on travel
- 03/29/22
- United Airlines Ventures, Oxy Low Carbon Ventures partner with Cemvita Factory
- 04/21/22
- Take-Two to publish new 'Tales from the Borderlands' title in 2022
- 04/06/22
- Remedy to remake first two 'Max Payne' games in partnership with Rockstar
- 03/28/22
- Take-Two's Rockstar announces GTA+ membership program for PS5, Xbox Series
- 03/15/22
- Take-Two announces availability of 'Grand Theft Auto V' on latest consoles
- 03/24/22
- Spire Global expands relationship with Slingshot Aerospace
- 03/16/22
- Spire Global announces space-as-a-service agreement with NorthStar Earth & Space
- 03/07/22
- Spire Global, Sierra Nevada announce strategic partnership
- 02/11/22
- Spire Global trading resumes
- 04/14/22
- Super Group falls -9.0%
- 02/23/22
- Super Group reports preliminary FY21 net gaming revenue over $1.52B, up 36%
- 01/27/22
- Sports Entertainment Acquisition, Super Group announce closing of combination
- 01/26/22
- Sports Entertainment Acquisition holders approve merger with Super Group
MIST Milestone Pharmaceuticals - 02/16/22
- Milestone Pharmaceuticals names David Bharucha as Chief Medical Officer
- 11/15/21
- Milestone Pharmaceuticals announces presentation of NODE-301 trial of etripamil
- 04/14/22
- Land's End launching on-air collaboration with QVC
- 03/16/22
- Land's End drops 10% to $14.25 after Q4 results, FY22 guidance miss estimates
- 03/16/22
- Land's End CFO sees FY22 sales growth higher in 'back half of the year'
- 03/10/22
- Kilroy Realty announces acquisition of strategic Austin development site
- 10/27/21
- Kilroy Realty raises quarterly dividend 4% to 52c per share
- 04/20/22
- JetBlue Technology Ventures makes limited partner investment in TPG Rise Climate
- 04/10/22
- Fly Intel: Top five weekend stock stories
- 04/08/22
- Spirit Airlines to begin discussions with JetBlue
- $11.77 /
-2.515 (-17.61%) - 04/22/22
- Gap falls -22.2%
- 04/22/22
- Gap falls -21.2%
- 04/21/22
- Gap falls over 4% to $13.63 after cutting Q1 sales outlook
- 04/21/22
- Gap cuts Q1 sales growth to 'low-to-mid-teen decline'
- 04/21/22
- Electronic Arts announces EA SPORTS F1 22 releasing worldwide on July 1
- 03/30/22
- EA's 'Apex Legends' next-generation update now live
- 03/29/22
- Electronic Arts CEO sells $1.29M in common stock
- 03/22/22
- Electronic Arts says 'EA Sports PGA Tour' out Spring 2023
- 04/21/22
- Dow Inc. to expand alkoxylation capacity in U.S., Europe to meet demand
- 04/21/22
- Dow Inc. sees FY22 base business core revenue up high-single digit percent range
- 04/21/22
- Dow Inc. says geopolitical environment remains dynamic
- 04/13/22
- Dow Inc. announces new $3B share repurchase pgoram
- $125.67 /
-1.645 (-1.29%) - 04/20/22
- North American rail traffic fell 7.5% for the week ending April 16
- 04/13/22
- North American rail traffic fell 1% for the week ending April 9
- 04/06/22
- North American rail traffic fell 0.5% for the week ending April 2
- 03/30/22
- North American rail traffic fell 4.5% for the week ending March 26
CGTX Cognition Therapeutics - 03/30/22
- Cognition Therapeutics expects cash to fund operations into second half of 2023
- 03/10/22
- Cognition Therapeutics to present analyses from studies of CT1812
- 01/10/22
- Cognition Therapeutics provides update on goals for 2022
- 01/04/22
- Cognition Therapeutics receives grant from Micheal J. Fox Foundation
- 02/16/22
- Boston Properties says construction resumes on Platform 16 Project in San Jose
- 01/20/22
- Boston Properties partners with Senseware on indoor air quality
- 12/06/21
- Boston Properties says JV executs lease with 'leading biotech company'
- 12/02/21
- TScan Therapeutics establishes facility to manufacture T Cell Therapies
- 03/16/22
- AeroVironment up 9% as President Biden confirms plans to provide Ukraine drones
- 02/15/22
- AeroVironment awarded $8.54M DoD contract
- 02/09/22
- AeroVironment awarded $10.5M contract
- 12/17/21
- Nauticus Robotics to become public via merger with CleanTech Acquisition
- 04/12/22
- American Airlines sees Q1 CASM up 12%-13% vs. 1Q19
- 04/12/22
- XPO appoints David Phalen as SVP, pricing for North American LTL network
- 03/23/22
- JetBlue, American announce 'perks' for TrueBlue Mosaic and AAdvantage members
- 04/22/22 MKM Partners
- United Airlines price target raised to $59 from $53 at MKM Partners
- 04/22/22 Morgan Stanley
- United Airlines price target raised to $67 from $62 at Morgan Stanley
- 04/22/22 Argus
- United Airlines upgraded to Buy from Hold at Argus
- 04/22/22 Cowen
- United Airlines price target raised to $86.50 from $78 at Cowen
- 04/22/22 Argus
- American Airlines upgraded to Buy from Hold at Argus
- 04/22/22 JPMorgan
- American Airlines upgraded to Neutral with $26 target at JPMorgan
- 04/22/22 Deutsche Bank
- American Airlines price target raised to $25 from $23 at Deutsche Bank
- 04/22/22 Barclays
- American Airlines price target raised to $20 from $15 at Barclays
MIST Milestone Pharmaceuticals - 04/21/22 Piper Sandler
- Piper upgrades Milestone Pharmaceuticals on etripamil confidence
- 04/21/22 Piper Sandler
- Milestone Pharmaceuticals upgraded to Overweight from Neutral at Piper Sandler
- 04/22/22 Mizuho
- Mizuho upgrades Boston Properties, names top office REIT pick
- 04/21/22 Mizuho
- Boston Properties upgraded to Buy from Neutral at Mizuho
- 04/14/22 Deutsche Bank
- Boston Properties price target raised to $139 from $131 at Deutsche Bank
- 03/03/22 Evercore ISI
- Evercore ISI shakes up Office REIT ratings with one upgrade, two downgrades
- 04/14/22 Deutsche Bank
- Kilroy Realty price target raised to $75 from $74 at Deutsche Bank
- 03/03/22 Evercore ISI
- Kilroy Realty downgraded to In Line from Outperform at Evercore ISI
- 04/22/22 BMO Capital
- Dow Inc. price target raised to $76 from $65 at BMO Capital
- 04/22/22 JPMorgan
- Dow Inc. price target raised to $80 from $70 at JPMorgan
- 04/22/22 Deutsche Bank
- Dow Inc. price target raised to $74 from $66 at Deutsche Bank
- 04/22/22 RBC Capital
- Dow Inc. price target raised to $70 from $62 at RBC Capital
- 04/22/22 Deutsche Bank
- JetBlue downgraded to Hold on headwinds at Deutsche Bank
- 04/22/22 Deutsche Bank
- JetBlue downgraded to Hold from Buy at Deutsche Bank
- 04/12/22 Wolfe Research
- JetBlue downgraded to Underperform from Peer Perform at Wolfe Research
- 04/11/22 MKM Partners
- JetBlue upgraded to Neutral at MKM Partners on valuation
- 04/22/22 Baird
- Baird downgrades AeroVironment, sees Switchblade demand baked in after rally
- 04/22/22 Baird
- AeroVironment downgraded to Neutral from Outperform at Baird
- 03/17/22 Baird
- AeroVironment price target raised to $95 from $72 at Baird
- 03/04/22 Canaccord
- AeroVironment upgraded at Canaccord on potential for exports amid war in Europe
- 04/22/22 Raymond James
- Union Pacific price target raised to $285 from $280 at Raymond James
- 04/22/22 UBS
- UBS cuts Union Pacific to Neutral on capacity constraints and service issues
- 04/22/22 UBS
- Union Pacific downgraded to Neutral from Buy at UBS
- 04/22/22 Susquehanna
- Union Pacific good for new money investors, says Susquehanna
- $125.67 /
-1.645 (-1.29%) - 04/22/22 Raymond James
- Canadian National downgraded to Market Perform from Outperform at Raymond James
- 04/14/22 CIBC
- Canadian National price target raised to C$169 from C$165 at CIBC
- 04/08/22 National Bank
- Canadian National price target lowered to C$168 from C$172 at National Bank
- 04/08/22 JPMorgan
- Canadian National price target lowered to C$159 from C$171 at JPMorgan
- 04/22/22 Craig-Hallum
- Land's End downgraded to Hold from Buy at Craig-Hallum
- 03/17/22 Craig-Hallum
- Land's End price target lowered to $35 from $45 at Craig-Hallum
- 07/21/21 Craig-Hallum
- Land's End price target raised to $60 from $50 at Craig-Hallum
- 06/03/21 Craig-Hallum
- Land's End price target raised to $50 from $45 at Craig-Hallum
- $11.77 /
-2.515 (-17.61%) - 04/22/22 B. Riley
- Gap price target lowered to $13 from $15 at B. Riley
- 04/22/22 BMO Capital
- Gap price target lowered to $13 from $16 at BMO Capital
- 04/22/22 Baird
- Gap price target lowered to $14 from $18 at Baird
- 04/21/22 Raymond James
- Spire Global initiated with an Outperform at Raymond James
- 03/28/22 CJS Securities
- Spire Global initiated with an Outperform at CJS Securities
- 03/03/22 Stifel
- Spire Global initiated with a Buy at Stifel
- 01/19/22 BofA
- Spire Global downgraded to Underperform at BofA on valuation
- 04/22/22 Bernstein
- Electronic Arts initiated with an Outperform at Bernstein
- 04/21/22 Stifel
- Electronic Arts price target lowered to $155 from $165 at Stifel
- 04/19/22 Goldman Sachs
- Electronic Arts assumed with Neutral from Buy at Goldman Sachs
- 02/02/22 Stifel
- Electronic Arts price target lowered to $165 from $173 at Stifel
- 04/22/22 Bernstein
- Take-Two initiated with an Outperform at Bernstein
- 04/19/22 Goldman Sachs
- Take-Two assumed with Not Rated at Goldman Sachs
- 04/07/22 Benchmark
- 'Max Payne' remake not included in Take-Two FY23-FY25 guidance, says Benchmark
- 04/06/22 BofA
- Take-Two reinstated with a Buy at BofA
CGTX Cognition Therapeutics - 04/22/22 Ladenburg
- Cognition Therapeutics initiated with a Buy at Ladenburg
- 01/24/22 B. Riley
- Cognition Therapeutics price target lowered to $20 from $27 at B. Riley
- 11/03/21
- Fly Intel: Top five analyst initiations
- 11/03/21 B. Riley
- Cognition Therapeutics initiated with a Buy at B. Riley
- 04/22/22 Canaccord
- Canaccord starts 'consistently profitable' Super Group at Buy
- 04/22/22 Canaccord
- Super Group initiated with a Buy at Canaccord
- 04/14/22 Benchmark
- Super Group price target lowered to $14 from $16 at Benchmark
- 03/14/22 Needham
- Super Group initiated with a Buy at Needham
- 04/21/22
- Union Pacific reports Q1 EPS $2.57, consensus $2.55
- 01/20/22
- Union Pacific reports Q4 EPS $2.66, consensus $2.61
- 04/20/22
- United Airlines reports Q1 adjusted EPS ($4.24), consensus ($4.21)
- 04/20/22
- Notable companies reporting after market close
- 03/15/22
- United Airlines sees Q1 capacity down approximately 19%
- 01/19/22
- United Airlines sees FY22 capacity down vs 2019
- 02/07/22
- Take-Two sees FY22 GAAP EPS $3.10-$3.20, consensus $4.81
- 02/07/22
- Take-Two raises FY22 net bookings view to $3.37B-$3.42B, consensus $3.49B
- 02/07/22
- Take-Two sees Q4 EPS 46c-56c, consensus $1.15
- 02/07/22
- Take-Two reports Q3 GAAP EPS $1.24, consensus $1.23
- 03/09/22
- Spire Global sees FY22 adjusted EPS (44c)-(41c), consensus (39c)
- 03/09/22
- Spire Global sees Q1 adjusted EPS (14c)-(13c), consensus (11c)
- 03/09/22
- Spire Global reports preliminary Q4 EPS 38c, consensus (13c)
- 01/31/22
- Spire Global sees FY22 revenue $85M-$90M, consensus $72.3M
MIST Milestone Pharmaceuticals - 03/24/22
- Milestone Pharmaceuticals reports Q4 EPS (40c), consensus (36c)
- 11/12/21
- Milestone Pharmaceuticals reports Q3 EPS (34c), consensus (38c)
- 03/16/22
- Land's End sees FY22 EPS 71c-$1.04, consensus $1.14
- 03/16/22
- Land's End sees Q1 EPS (12c)-(6c), consensus (26c)
- 03/16/22
- Land's End reports Q4 EPS 21c, consensus 31c
- 12/02/21
- Land's End lowers FY21 EPS view to $1.04-$1.13 from $1.35-$1.51, consensus $1.42
- 01/31/22
- Kilroy Realty reports Q4 FFO $1.05, consensus 95c
- 10/27/21
- Kilroy Realty reports Q3 FFO 98c, consensus 94
- 01/27/22
- JetBlue sees Q1 revenue down 11%-16%
- 01/27/22
- JetBlue reports Q4 EPS (36c), consensus (39c)
- 01/26/22
- Notable companies reporting before tomorrow's open
- $11.77 /
-2.515 (-17.61%) - 03/03/22
- Gap sees FY22 adjusted EPS $1.85-$2.05, consensus $1.86
- 03/03/22
- Gap reports Q4 adjusted EPS (2c), consensus (14c)
- 03/03/22
- Notable companies reporting after market close
- 11/23/21
- Gap reports Q3 Old Navy SSS down 9% y/y
- 02/01/22
- Electronic Arts raises FY22 EPS view to $2.43 from $2.03, consensus $6.86
- 02/01/22
- Electronic Arts sees Q4 EPS 46c, consensus $1.45
- 02/01/22
- Electronic Arts reports Q3 GAAP EPS 23c, consensus $3.22
- 02/01/22
- Notable companies reporting after market close
- 04/21/22
- Dow Inc. reports Q1 operating EPS $2.34, consensus $2.05
- 01/27/22
- Dow Inc. reports Q4 operating EPS $2.15, consensus $2.04
- $125.67 /
-1.645 (-1.29%) - 01/25/22
- Canadian National sees FY22 adjusted EPS up 20%
- 01/25/22
- Canadian National reports Q4 adjusted EPS C$1.71 vs. C$1.43 last year
CGTX Cognition Therapeutics - 03/30/22
- Cognition Therapeutics reports 2021 EPS ($3.13) vs ($23.76) last year
- 11/18/21
- Cognition Therapeutics reports Q3 EPS ($8.12), one estimate (57c)
- 01/25/22
- Boston Properties sees FY22 FFO $7.30-$7.45, consensus $7.33
- 01/25/22
- Boston Properties sees Q1 FFO $1.72-$1.74, consensus $1.73
- 01/25/22
- Boston Properties reports Q4 FFO $1.55, consensus $1.52
- 10/26/21
- Boston Properties reports Q3 FFO $1.73, consensus $1.70
- 03/03/22
- AeroVironment sees FY22 $1.23-$1.37, consensus $1.30
- 03/03/22
- AeroVironment reports Q3 EPS 32c, consensus 30c
- 12/07/21
- AeroVironment lowers 2022 sales outlook to $440M-$460M from $560M-$580M
- 12/07/21
- AeroVironment reports Q2 adjusted EPS 78c, consensus 62c
- 04/21/22
- American Airlines sees Q2 revenue up 6%-8% vs. last year, consensus $11.26B
- 04/21/22
- American Airlines reports Q1 EPS ex-items ($2.32), consensus ($2.40)
- 04/20/22
- Notable companies reporting before tomorrow's open
|
|
Upgrade
|
Piper Sandler analyst… Piper Sandler analyst Edward Tenthoff upgraded Milestone Pharmaceuticals to Overweight from Neutral with a price target of $10, up from $8, after hosting a call with Dr. Bruce Stambler of the Piedmont Heart Institute on etripamil to treat paroxysmal supra-ventricular tachycardia. The analyst is now confident etripamil can meet the primary endpoint of time to conversion to normal sinus rhythm within 30 minutes. Additionally, patients can administer a second dose of etripamil if PSVT symptoms persist for over 10 minutes, further increasing the likelihood of conversion, Tenthoff tells investors in a research note. He adds that Milestone ended 2021 with cash of $114M, which should fund operations into the second half of 2023. ShowHide Related Items >><< MIST Milestone Pharmaceuticals - 02/16/22
- Milestone Pharmaceuticals names David Bharucha as Chief Medical Officer
- 11/15/21
- Milestone Pharmaceuticals announces presentation of NODE-301 trial of etripamil
MIST Milestone Pharmaceuticals - 04/21/22 Piper Sandler
- Milestone Pharmaceuticals upgraded to Overweight from Neutral at Piper Sandler
MIST Milestone Pharmaceuticals - 03/24/22
- Milestone Pharmaceuticals reports Q4 EPS (40c), consensus (36c)
- 11/12/21
- Milestone Pharmaceuticals reports Q3 EPS (34c), consensus (38c)
|
